<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>Among these, in decreasing frequency of occurrence, are:</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral T cell lymphoma, not otherwise specified</p><p class="bulletIndent1"><span class="glyph">●</span>Anaplastic large cell lymphoma, primary systemic type</p><p class="bulletIndent1"><span class="glyph">●</span>Angioimmunoblastic T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Extranodal NK/T cell lymphoma, nasal type</p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous panniculitis-like T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Enteropathy associated T cell lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenic T cell lymphoma</p><p></p><p>Angioimmunoblastic T cell lymphoma (AITL) is one of the more common PTCLs and is thought to arise from a subset of peripheral CD4 positive T cells corresponding to follicular helper T cells [<a href="#rid3">3-5</a>]. Patients typically present with the acute onset of a systemic illness and lymph node biopsy demonstrates a polymorphous infiltrate with a prominent proliferation of high endothelial venules and follicular dendritic cells.</p><p>In the past, AITL was thought to arise from an abnormal immune reaction, frequently accompanied by dysproteinemia. This was referred to as "angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)." It has since been realized that essentially all cases of AILD have clonal rearrangements of T cell receptor genes and represent a frank T cell lymphoma rather than a benign entity with high risk for transformation to one. Moreover, genomic sequencing of AITL has revealed the presence of acquired "driver" mutations in genes previously linked to the pathogenesis of other hematologic cancers.     </p><p>The clinical presentation, pathologic features, and diagnosis of AITL will be discussed here. The other T cell lymphomas, including the NK/T cell types, and the pathobiology and treatment of the PTCLs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a> and  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type"</a> and  <a class="medical medical_review" href="/z/d/html/16591.html" rel="external">"Treatment of extranodal NK/T cell lymphoma, nasal type"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Angioimmunoblastic T cell lymphoma (AITL) is one of the more common peripheral T cell lymphomas (PTCL) encountered in Western countries. Incidence varies by geography. The highest incidence rates are in Europe (28 percent of PTCL), while lower rates are seen in North America (15 percent of PTCL) and Asia (17 percent of PTCL) [<a href="#rid6">6,7</a>]. In the United States the incidence is approximately 0.05 cases per 100,000 person years [<a href="#rid8">8</a>].</p><p>In the United States, the incidence is higher among Asian/Pacific Islanders and Hispanic White Americans and lowest among non-Hispanic White and Black Americans [<a href="#rid9">9</a>]. It is uncommon in Native Americans and Alaska natives.  </p><p>AITL usually affects older adults; the median age is approximately 60 to 65 years (range 20 to 86 years) [<a href="#rid10">10-13</a>]. Some reports have noted a slight male predominance [<a href="#rid10">10-13</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with angioimmunoblastic T cell lymphoma (AITL) typically present with the acute onset of a systemic illness. Less commonly, patients may present with asymptomatic lymphadenopathy.</p><p>Symptoms frequently include [<a href="#rid11">11,13-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Generalized lymphadenopathy (76 to 95 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly (50 to 70 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly (70 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic B symptoms of fevers, night sweats, or weight loss (70 to 85 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Rash (20 to 60 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Polyarthritis (20 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Ascites/effusions (20 to 35 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms related to anemia (20 to 50 percent)</p><p></p><p>The rash is usually pruritic and may demonstrate lymphohistiocytic vasculitis on biopsy. The vast majority (90 percent) of patients present with advanced (stage III/IV) disease. The bone marrow is involved in 30 to 60 percent of cases. While extranodal involvement is present in approximately one-quarter, it is uncommon for AITL to present at a single, isolated extranodal site [<a href="#rid13">13</a>].</p><p>Laboratory abnormalities are common and include [<a href="#rid11">11,14-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR), seen in approximately 70 and 45 percent of cases, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyclonal hypergammaglobulinemia, present in 30 to 80 percent of cases; other cases may demonstrate hypogammaglobulinemia or a monoclonal gammopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive Coombs test, with or without hemolysis, seen in up to 30 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated beta-2 microglobulin (22 to 65 percent of cases).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphopenia, anemia, and thrombocytopenia, seen in approximately 45 percent, 30 to 50 percent, and 20 to 25 percent of cases, respectively. Hypereosinophilia is noted in another 30 to 40 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately half of patients demonstrate hypoalbuminemia.</p><p></p><p>Immunologic abnormalities are common and can include plasmacytosis, polyclonal hypergammaglobulinemia, and a positive Coombs test [<a href="#rid18">18</a>]. AITL can be associated with autoimmune phenomena including hemolytic anemia, vasculitis, polyarthritis, rheumatoid arthritis, and thyroid disease [<a href="#rid13">13,17</a>]. Cold agglutinins and cryoglobulins can also be seen. These autoimmune features are thought to stem from immune dysregulation of both B cells and T cells that result in immunodeficiency and risk of opportunistic infections before and during treatment.</p><p class="headingAnchor" id="H4"><span class="h1">PATHOLOGIC FEATURES</span></p><p class="headingAnchor" id="H5"><span class="h2">Morphology</span></p><p class="headingAnchor" id="H6"><span class="h3">Growth pattern</span><span class="headingEndMark"> — </span>Involved lymph nodes demonstrate partial or complete effacement of the normal architecture by a predominantly paracortical infiltrate of atypical lymphoid and inflammatory cells [<a href="#rid1">1</a>]. Follicles may be hyperplastic, depleted, or absent. Peripheral sinuses are typically open or even dilated, and the abnormal infiltrate usually does not extend beyond the capsule into perinodal tissue.</p><p>There is prominent neovascularization with arborizing high endothelial venules (HEV), many of which show thickened or hyalinized walls  (<a class="graphic graphic_picture graphicRef86422" href="/z/d/graphic/86422.html" rel="external">picture 1</a>). This can be particularly well appreciated with a Periodic Acid Schiff (PAS) stain. Clusters of epithelioid histiocytes and numerous eosinophils and plasma cells may be present. Expanded aggregates of follicular dendritic cells, best appreciated in sections immunostained for dendritic cell markers, surround the proliferating blood vessels, and may have the appearance of "burned-out" germinal centers.</p><p class="headingAnchor" id="H7"><span class="h3">Cell morphology</span><span class="headingEndMark"> — </span>The infiltrating cells are a mixture of variably sized lymphocytes, immunoblasts, polyclonal plasma cells, eosinophils, histiocytes, epithelioid cells, and medium-sized atypical lymphoid cells with round or irregular nuclei and moderately abundant clear cytoplasm  (<a class="graphic graphic_picture graphicRef86423" href="/z/d/graphic/86423.html" rel="external">picture 2</a>). In the past, this polymorphous mixture of cell types was interpreted to be a reactive process (angioimmunoblastic lymphadenopathy with dysproteinemia). As the neoplasm progresses, lymphoid cells with clear cytoplasm tend to increase in number and efface the lymph node. In most cases, these clear cells are closely associated and intermingled with the expanded follicular dendritic cell (FDC) network. B immunoblasts may be numerous in areas between the FDCs and often harbor Epstein-Barr virus (EBV). The malignant T cells and the background reactive component generally do not penetrate beyond the lymph node capsule, but infiltration into the perinodal fat is sometimes seen. B immunoblasts that are EBV-positive are sometimes very prominent and occasionally give rise to secondary EBV-positive diffuse large B cell lymphoma (DLBCL). Occasionally, binucleated or multinucleated cells that resemble the Reed-Sternberg (RS) cells of Hodgkin lymphoma may be observed. These RS-like cells are usually EBV-positive and may be akin to similar appearing cells that are found on occasion in lymph nodes of patients with infectious mononucleosis. However, the inflammatory background that is characteristic of true classic Hodgkin lymphoma is absent.</p><p class="headingAnchor" id="H8"><span class="h3">Bone marrow involvement</span><span class="headingEndMark"> — </span>Bone marrow involvement in angioimmunoblastic T cell lymphoma (AITL) usually takes the form of paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes mixed with histiocytes and eosinophils [<a href="#rid19">19</a>]. The lymphomatous infiltrate in some marrow specimens contains numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma. Secondary changes such as trilineage hyperplasia of marrow elements and polyclonal plasmacytosis are frequent and may present independent of marrow involvement.</p><p class="headingAnchor" id="H9"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>AITL tumor cells appear to be the malignant counterparts of CD4-positive T follicular helper (Tfh) cells, which normally provide T cell help to germinal center B cells. The tumor cells express pan T cell antigens (ie, CD3, CD2, and CD5) and almost always express CD4  (<a class="graphic graphic_picture graphicRef86424" href="/z/d/graphic/86424.html" rel="external">picture 3</a>); CD3 expression may be dim or absent, particularly in the peripheral blood, which shows low-level involvement in approximately half of patients [<a href="#rid20">20</a>]. Many reactive CD8-expressing T cells are often present. An expanded follicular dendritic cell (FDC) network expressing CD21, CD23, and CD35 is usually present, often in areas where malignant T cells with abundant pale cytoplasm are seen  (<a class="graphic graphic_picture graphicRef86425" href="/z/d/graphic/86425.html" rel="external">picture 4</a>) [<a href="#rid21">21,22</a>]. This feature is useful in distinguishing this disorder from other T cell lymphomas, which do not contain expanded populations of FDCs [<a href="#rid7">7</a>].</p><p>The malignant T cells frequently express CD10, CXCL13, PD-1, BCL6, and ICOS, markers that are expressed by normal Tfh cells [<a href="#rid1">1,23-25</a>]. As an example, in one study, CD10 positive T cells were found in 27 of 30 cases of AITL [<a href="#rid23">23</a>]. In contrast, no CD10 positive T cells were present in 10 cases of other peripheral T cell lymphomas or 10 cases of reactive lymphoid hyperplasia. Single cell studies indicated that the CD10 positive cells belonged to the neoplastic clone.</p><p class="headingAnchor" id="H10"><span class="h2">Genetic features</span><span class="headingEndMark"> — </span>T cell receptor genes are clonally rearranged in 75 to 90 percent of cases; immunoglobulin heavy chains may be clonally rearranged in up to 25 percent, corresponding to the secondarily expanded Epstein-Barr virus-positive B cell clones [<a href="#rid22">22,26</a>]. Human herpes virus-6 (HHV6) genomes also are detected in many cases and may be present in either T or B cells [<a href="#rid27">27-29</a>].</p><p>Many genetic abnormalities have been reported, but there is no single cytogenetic change that is typical or diagnostic of AITL. The most common cytogenetic abnormalities are trisomy 3, trisomy 5, and/or an additional X chromosome [<a href="#rid1">1,30</a>]. There is also an unusually high incidence of subclones with distinct chromosomal aberrations; the mechanism underlying the apparent genomic instability is unknown. Gene expression profiling demonstrates a pattern similar to that expressed by follicular helper T cells [<a href="#rid5">5,31</a>].</p><p>Of interest, among peripheral T cell lymphomas, AITL is particularly likely to have mutations in the genes <em>TET2, IDH2, DNMT3A, </em>and<em> RHOA</em> [<a href="#rid31">31-34</a>]. In one study, <em>TET2</em> mutations were identified in 40 of 86 AITLs (47 percent) [<a href="#rid32">32</a>], while a second study identified <em>IDH2</em> mutations in 20 to 45 percent of AITLs [<a href="#rid33">33</a>]. Unlike in acute myeloid leukemia (AML), <em>IDH2</em> mutations preferentially occur at R172 and coexist with <em>TET2</em> mutations more frequently than in AML [<a href="#rid31">31</a>]. The pathogenic significance of these mutations in AITL is uncertain, but it is of interest that mutations in the same genes in myeloid neoplasms lead to changes in DNA methylation and appear to increase the self-renewal capacity of hematopoietic stem cells. AITL may originate from mutated hematopoietic stem cells (rather than peripheral T cells) because B cells from patients with AITL often contain the same <em>TET2</em> and/or <em>DNMT3A</em> mutations as are found in AITL cells [<a href="#rid35">35,36</a>]. </p><p><em>RHOA</em>, a gene that encodes a small GTP-binding protein, is mutated in roughly at least half of cases, often in association with <em>TET2</em> mutation; a glycine to valine substitution in residue 17 in <em>RHOA</em>, dominates in AITL [<a href="#rid37">37-39</a>]. Consistent with a central role for this mutation, studies in mice have shown that expression of RHOA G17V in CD4<sup>+</sup> T cells induces Tfh cell specification, PI3k and Mapk signaling, increased proliferation and, when combined with Tet2 loss, results in development of AITL [<a href="#rid40">40</a>]. In another mouse model of AITL, it is proposed that interactions between malignant T cells and adjacent B lymphocytes are necessary for tumor progression; if extended to human AITL, these observations may provide novel therapeutic opportunities [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of angioimmunoblastic T cell lymphoma (AITL) is best made by excisional tissue biopsy, most commonly a lymph node interpreted in the context of the clinical presentation. Lymph node evaluation includes assessment of the morphology and immunophenotyping, which are essential to make the diagnosis  (<a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">table 1</a>). In difficult cases, PCR-based tests to look for the presence of clonal T cell receptor rearrangements can be helpful.</p><p>As described above, tissue sections reveal effaced nodal architecture, prominent arborizing high endothelial venules, and a polymorphous infiltrate including reactive lymphocytes, immunoblasts, plasma cells, inflammatory cells, and small to large atypical lymphocytes that are positive for CD3 and CD4. Many cases also are positive for markers that are expressed by normal Tfh cells, such as BCL6, CD10, CXCL13, PD-1, and ICOS. As with other peripheral T cell lymphomas, the tumor cells may lose a subset of pan-T cell markers and exhibit an aberrant immunophenotype. Follicular dendritic cells (FDCs) are inconspicuous in routinely stained sections, but immunohistochemical staining for markers such as CD21 usually demonstrates irregularly shaped expansions of these cells.</p><p>When clusters of atypical T cells with abundant clear cytoplasm are present, they are typically found within the expanded FDC network. In most cases, Epstein-Barr virus (EBV) positive B immunoblasts, best detected by in situ hybridization for small nuclear EBV RNAS (EBERs), are present in areas between the FDCs. (See  <a class="medical medical_review" href="/z/d/html/8276.html" rel="external">"Virology of Epstein-Barr virus", section on 'EBER-1 and EBER-2'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H13"><span class="h2">Other peripheral T cell lymphomas</span><span class="headingEndMark"> — </span>Both angioimmunoblastic T cell lymphoma (AITL) and other peripheral T cell lymphomas (PTCLs) typically express pan T cell associated antigens (ie, CD3, CD2, and CD5) and demonstrate T cell receptor gene rearrangements. AITL is distinguished from most other PTCLs by expression of BCL6, CD10, CXCL13, PD-1, and ICOS and the presence of expanded meshworks of follicular dendritic cells (FDCs) expressing CD21, CD23, and CD35. FDCs are not expanded in other PTCLs.</p><p>In the 2016 revision of the WHO classification, the category of peripheral T cell lymphoma includes two provisional entities in addition to AITL that, like AITL, appear to share an origin from T follicular helper cells [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Follicular T cell lymphoma </p><p class="bulletIndent1"><span class="glyph">●</span>Nodal peripheral T cell lymphoma with T follicular helper (Tfh) phenotype </p><p></p><p>Such tumors have neoplastic cells that express at least two Tfh-related antigens, including CD279/PD1, CD10, BCL6, CXCL13, ICOS, SAP, and CCR5. Patients with follicular T cell lymphoma usually present with localized disease and few symptoms, whereas nodal peripheral T cell lymphomas with TFH phenotypes encompass cases that lack histologic features typical of AITL. In addition to phenotypic similarities to AITL, tumors in these provisional categories also share many of the same somatic mutations, including mutations in the genes <em>TET2, IDH2, DNMT3A, RHOA, </em>and<em> CD28</em>. </p><p class="headingAnchor" id="H14"><span class="h2">Hodgkin lymphoma</span><span class="headingEndMark"> — </span>Occasionally, binucleated or multinucleated cells that resemble the Reed-Sternberg (R-S) cells of Hodgkin lymphoma (HL) may be observed in angioimmunoblastic T cell lymphoma. These cells can even exhibit the immunophenotypic characteristics of true R-S cells, making distinction from HL difficult. However, unlike in HL, clonal T cell receptor gene rearrangements are present in most cases of AITL. The prominent vascular proliferation and the proliferation of atypical T cells with clear cytoplasm are absent in HL. </p><p class="headingAnchor" id="H1022779"><span class="h2">EBV-positive diffuse large B cell lymphoma, NOS</span><span class="headingEndMark"> — </span>EBV-positive diffuse large B cell lymphoma, not otherwise specified, is a subtype of B cell lymphoma characterized by the presence of numerous large EBV+ B cells and that often involves extranodal sites. Vascular invasion by the tumor cells may produce tissue necrosis. The EBV+ B cells in AITL are usually scattered, but in instances where small biopsies are taken, EBV+ B cells (usually detected by in situ hybridization for EBV EBER RNAs) can be sufficiently numerous to cause diagnostic confusion. The keys to making the distinction are recognition of the underlying T cell proliferation and performance of gene rearrangements studies, which typically show a polyclonal B cell population in AITL. (See  <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'EBV-positive DLBCL, NOS'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of angioimmunoblastic T cell lymphoma (AITL) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma", section on 'Outcomes by PTCL subtype'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>AITL is generally an aggressive disease, although occasional spontaneous remissions are seen. The AITL prognostic score [<a href="#rid42">42</a>], which is based on clinical and laboratory features [<a href="#rid42">42</a>] appears to have greater discriminant power than either the International Prognostic Index (IPI)  (<a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">table 2</a>) or the Prognostic Index for T cell lymphomas (PIT) [<a href="#rid13">13,24,43,44</a>]. The course of disease is not reliably predicted by the histologic appearance, but outcomes are associated with gene expression patterns. </p><p>The international prospective T-cell Project (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT01142674&amp;token=YbJELcAW9G3aZfZrjTwgllXLsXNNrpAr426VqXdy7dLaR6MKR2fCoY01n%2FWzQhvLLnnS%2FKHELNLogrwP4olIww%3D%3D&amp;TOPIC_ID=4727" target="_blank">NCT01142674</a>) reported outcomes for 282 patients with AITL and developed and validated a prognostic score (AITL score) based on clinical and laboratory features [<a href="#rid42">42</a>]. Median age of patients was 64 years, 90 percent had advanced-stage disease, 81 percent received anthracycline-based chemotherapy, and 13 percent underwent consolidative autologous hematopoietic cell transplantation (HCT) in first complete remission (CR1). Five-year overall survival (OS) and progression-free survival (PFS) were 44 and 32 percent, respectively, and outcomes were more favorable for patients who underwent autologous HCT in CR1. Multivariate analysis reported that age ≥60 years, Eastern Cooperative Oncology Group (ECOG) performance status &gt;2, elevated C-reactive protein, and elevated beta 2 microglobulin were associated with inferior outcomes. A prognostic score based on these factors (AITL score) defined subgroups with distinct five-year OS: low-risk (63 percent), intermediate-risk (54 percent), and high-risk (21 percent). In addition, progression of disease within 24 months (POD24) was a powerful prognostic factor, with 63 percent five-year OS for patients without progression, compared with 6 percent for patients with POD24. </p><p>A retrospective analysis from Japan of 207 patients with AITL with a median follow-up of 42 months reported three-year OS and PFS rates of 54 and 38 percent, respectively [<a href="#rid45">45</a>]. Three-year OS according to IPI score was 81, 69, 53, and 35 percent for patients with low-, low-intermediate-, high-intermediate-, and high-risk IPI, respectively.</p><p>Analysis of gene expression studies in 66 patients with AITL reported that cases enriched for B lymphocytes had a more favorable prognosis [<a href="#rid46">46</a>]. The study detected the <em>RHOA</em> G17V mutation in one-third of patients and multivariate analysis reported that expression of a B cell signature (<em>TCL1A, PNOC, CD19, CD20, </em>and<em> SPIB</em>) was an IPI-independent prognostic factor. The B cell pattern segregated patients into high-risk and a low-risk categories that had distinct OS and time to progression (TTP). For the high-risk group, OS and TTP at 32 months were 30 percent and 20 percent, respectively, while for the low-risk group, the corresponding rates for OS and TTP were 75 percent and 70 percent. Compared with median OS, the hazard ratios (HR) for OS for the high-risk group was 0.35 (95% CI 0.14-0.85) compared with 2.73 (95% CI 1.37-6.86) for the low-risk group. The prognostic significance for OS and TTP was confirmed in a validation cohort of 27 patients with AITL.</p><p class="headingAnchor" id="H4123017465"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angioimmunoblastic T cell lymphoma (AITL)</strong> – AITL is one of the more common peripheral T cell lymphomas and is thought to arise from CD4+ T follicular helper cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients typically present with the acute onset of a systemic illness characterized by generalized lymphadenopathy, hepatosplenomegaly, systemic B symptoms (ie, fever, night sweats, weight loss), with or without a rash. It can also be associated with immunologic abnormalities, such as autoimmune hemolytic anemia, plasmacytosis, or polyclonal hypergammaglobulinemia. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of AITL is best made by excisional tissue biopsy, most commonly a lymph node interpreted in the context of the clinical presentation  (<a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">table 1</a>). The histology reveals effaced nodal architecture, prominent arborizing high endothelial venules, and a polymorphous infiltrate including small to large atypical lymphocytes that are positive for T cell markers and markers of T follicular helper cells. Expanded networks of follicular dendritic cells are also characteristically present and can be demonstrated by staining for markers such as CD21. (See <a class="local">'Pathologic features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – AITL should be distinguished from other peripheral T cell lymphomas, Hodgkin lymphoma, and Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Outcomes for patients have been associated with clinical and laboratory features (AITL score) and with patterns of gene expression. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 2005; 106:1501.</a></li><li><a class="nounderline abstract_t">Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood 2006; 108:1110.</a></li><li><a class="nounderline abstract_t">de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109:4952.</a></li><li><a class="nounderline abstract_t">Rudiger T, Weisenburger DD, Coiffier B, et al. Angioimmunoblastic T-cell Lymphoma: A report from the international peripheral T-cell lymphoma project. Ann Oncol 2008; 19(suppl 4):iv119.</a></li><li class="breakAll">Lennert K, Feller A. Histopathology of non-Hodgkin's lymphomas, Springer-Verlag, New York 1992.</li><li><a class="nounderline abstract_t">Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.</a></li><li><a class="nounderline abstract_t">Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol 2016; 34:963.</a></li><li><a class="nounderline abstract_t">Ohsaka A, Saito K, Sakai T, et al. Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer 1992; 69:1259.</a></li><li><a class="nounderline abstract_t">Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32:545.</a></li><li><a class="nounderline abstract_t">Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995; 6:659.</a></li><li><a class="nounderline abstract_t">Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31:240.</a></li><li><a class="nounderline abstract_t">Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127:140.</a></li><li><a class="nounderline abstract_t">Seehafer JR, Goldberg NC, Dicken CH, Su WP. Cutaneous manifestations of angioimmunoblastic lymphadenopathy. Arch Dermatol 1980; 116:41.</a></li><li><a class="nounderline abstract_t">Park BB, Ryoo BY, Lee JH, et al. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007; 48:716.</a></li><li><a class="nounderline abstract_t">Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003; 121:681.</a></li><li><a class="nounderline abstract_t">Sallah S, Gagnon GA. Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. Acta Haematol 1998; 99:57.</a></li><li><a class="nounderline abstract_t">Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 2007; 137:416.</a></li><li><a class="nounderline abstract_t">Loghavi S, Wang SA, Medeiros LJ, et al. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma 2016; 57:2804.</a></li><li><a class="nounderline abstract_t">Lee SS, Rüdiger T, Odenwald T, et al. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 2003; 103:12.</a></li><li><a class="nounderline abstract_t">Feller AC, Griesser H, Schilling CV, et al. Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 1988; 133:549.</a></li><li><a class="nounderline abstract_t">Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002; 99:627.</a></li><li><a class="nounderline abstract_t">Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111:4463.</a></li><li><a class="nounderline abstract_t">Marafioti T, Paterson JC, Ballabio E, et al. The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. Haematologica 2010; 95:432.</a></li><li><a class="nounderline abstract_t">Weiss LM, Strickler JG, Dorfman RF, et al. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 1986; 122:392.</a></li><li><a class="nounderline abstract_t">Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80:1804.</a></li><li><a class="nounderline abstract_t">Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79:1789.</a></li><li><a class="nounderline abstract_t">Zhou Y, Attygalle AD, Chuang SS, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007; 138:44.</a></li><li><a class="nounderline abstract_t">Schlegelberger B, Feller A, Gödde E, et al. Stepwise development of chromosomal abnormalities in angioimmunoblastic lymphadenopathy. Cancer Genet Cytogenet 1990; 50:15.</a></li><li><a class="nounderline abstract_t">Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 2015; 126:1741.</a></li><li><a class="nounderline abstract_t">Lemonnier F, Couronné L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120:1466.</a></li><li><a class="nounderline abstract_t">Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 2012; 119:1901.</a></li><li><a class="nounderline abstract_t">Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123:1293.</a></li><li><a class="nounderline abstract_t">Schwartz FH, Cai Q, Fellmann E, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol 2017; 242:129.</a></li><li><a class="nounderline abstract_t">Nguyen TB, Sakata-Yanagimoto M, Asabe Y, et al. Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J 2017; 7:e516.</a></li><li><a class="nounderline abstract_t">Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46:166.</a></li><li><a class="nounderline abstract_t">Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46:171.</a></li><li><a class="nounderline abstract_t">Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 2014; 46:371.</a></li><li><a class="nounderline abstract_t">Cortes JR, Ambesi-Impiombato A, Couronné L, et al. RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell 2018; 33:259.</a></li><li><a class="nounderline abstract_t">Witalis M, Chang J, Zhong MC, et al. Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. Blood Adv 2020; 4:868.</a></li><li><a class="nounderline abstract_t">Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood 2021; 138:213.</a></li><li><a class="nounderline abstract_t">International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987.</a></li><li><a class="nounderline abstract_t">Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.</a></li><li><a class="nounderline abstract_t">Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 2012; 119:2837.</a></li><li><a class="nounderline abstract_t">Rodríguez M, Alonso-Alonso R, Tomás-Roca L, et al. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Adv 2021; 5:5588.</a></li></ol></div><div id="topicVersionRevision">Topic 4727 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079436" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861359" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284527" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Angioimmunoblastic T-cell Lymphoma: A report from the international peripheral T-cell lymphoma project</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Angioimmunoblastic T-cell Lymphoma: A report from the international peripheral T-cell lymphoma project</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962200" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739925" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10048427" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664186" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869878" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461619" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bone marrow histopathology in peripheral T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6444351" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous manifestations of angioimmunoblastic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454629" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780782" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554450" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488486" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105079" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12455048" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849301" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781247" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292286" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207847" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082212" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327284" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1373088" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555446" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2253183" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Stepwise development of chromosomal abnormalities in angioimmunoblastic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26268241" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760778" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22215888" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24345752" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28337768" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28157189" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Identification of cell-type-specific mutations in nodal T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24413734" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24413737" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24584070" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398449" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32130407" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292324" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141877" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A predictive model for aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645001" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22308294" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34592752" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
